2023 Annual Meeting Knee Access Pass-Meniscal Scaffolds in the PostMeniscectomy Knee: What's the Current Role in 2023?

Meniscal Scaffolds in the PostMeniscectomy Knee: What's the Current Role in 2023?

Video Transcription

Video Summary

Manel Olivas-Meza discusses meniscal scaffolds (Actifit and CMI) as treatment after meniscectomy to slow cartilage deterioration. Studies show good medium-term clinical outcomes and patient satisfaction, despite some implant failures occurring within 5-7 years. Success depends on factors like defect length (<60mm), patient age (16-50), and minimal cartilage damage. Adding mesenchymal stem cells may improve tissue quality short-term. Scaffolds integrate well with native tissue, preserving cartilage and function, and may serve as a bridge before allograft transplantation. They are best suited for young patients with chronic, partial meniscal defects to relieve symptoms and delay joint degeneration.

Asset Caption

Anell Olivos-Meza, M.D.

Keywords

meniscal scaffolds

Actifit

CMI

meniscectomy treatment

cartilage preservation